Given the high rate of GBM tumor relapse and therapeutic resistance, the observed sensitivity of GBM CSCs to RIPK2-induced apoptosis has profound implications for the development of new therapies for GBM (Lucki et al., 2019). This evidence concerns the gene RIPK2 and glioblastoma.